Linden Thomas Advisory Services LLC Has $985,000 Stake in Xencor, Inc. (NASDAQ:XNCR)

Linden Thomas Advisory Services LLC reduced its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 1.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 42,877 shares of the biopharmaceutical company’s stock after selling 551 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Xencor were worth $985,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in XNCR. American Century Companies Inc. boosted its position in Xencor by 14.5% during the second quarter. American Century Companies Inc. now owns 95,375 shares of the biopharmaceutical company’s stock valued at $1,805,000 after purchasing an additional 12,083 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Xencor by 6.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,459,427 shares of the biopharmaceutical company’s stock valued at $27,628,000 after purchasing an additional 87,979 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Xencor by 49.8% in the second quarter. Renaissance Technologies LLC now owns 65,323 shares of the biopharmaceutical company’s stock valued at $1,237,000 after purchasing an additional 21,723 shares during the period. XTX Topco Ltd acquired a new stake in shares of Xencor in the second quarter worth $196,000. Finally, Public Sector Pension Investment Board boosted its holdings in shares of Xencor by 8.7% during the 2nd quarter. Public Sector Pension Investment Board now owns 135,657 shares of the biopharmaceutical company’s stock worth $2,568,000 after buying an additional 10,876 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages recently commented on XNCR. BMO Capital Markets reiterated an “outperform” rating and issued a $34.00 target price (up previously from $32.00) on shares of Xencor in a report on Friday, November 8th. Piper Sandler raised Xencor from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $20.00 to $30.00 in a research report on Monday, December 2nd. Wells Fargo & Company initiated coverage on Xencor in a report on Thursday, December 12th. They issued an “overweight” rating and a $37.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $38.00 price target on shares of Xencor in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. increased their price objective on Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Xencor currently has an average rating of “Buy” and a consensus price target of $34.88.

Xencor Stock Down 4.0 %

XNCR opened at $19.65 on Friday. The stock’s 50 day simple moving average is $23.56 and its 200-day simple moving average is $21.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a 1 year low of $15.31 and a 1 year high of $27.24.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.27. The firm had revenue of $10.70 million for the quarter, compared to analyst estimates of $14.59 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business’s revenue for the quarter was down 81.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.40) EPS. On average, analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Insider Activity at Xencor

In other Xencor news, Director Alan Bruce Montgomery sold 1,421 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total value of $38,409.63. Following the sale, the director now directly owns 9,140 shares in the company, valued at $247,054.20. This represents a 13.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP John R. Desjarlais sold 68,684 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the sale, the vice president now owns 200,104 shares in the company, valued at $4,698,441.92. This represents a 25.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 136,050 shares of company stock valued at $3,277,609 over the last quarter. 5.23% of the stock is owned by company insiders.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.